ISSN 1662-4009 (online)

ey0020.8-1 | Clinical Trials – New Treatments | ESPEYB20

8.1. Effect of Verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial

GP Forlenza , J McVean , RW Beck , C Bauza , R Bailey , B Buckingham , LA DiMeglio , JL Sherr , M Clements , A Neyman , C Evans-Molina , EK Sims , LH Messer , L Ekhlaspour , R McDonough , M Van Name , D Rojas , S Beasley , S DuBose , C Kollman , A Moran , CLVer Study Group

Brief summary: In this double-blind, randomized clinical trial conducted in 6 US centres, 88 children and adolescents (aged 7–17 years) with newly diagnosed type 1 diabetes (T1D) were randomized to either once-daily oral verapamil or placebo, within 1 month from diagnosis. Treatment with verapamil led to better stimulated C-peptide secretion at 52 weeks post-diagnosis, with levels 30% higher compared to placebo.Verapamil is a calcium channel blocker...

ey0020.10-2 | New Data on the Epidemiology of T2D in Children | ESPEYB20

10.2. The Coronavirus Disease 2019 pandemic is associated with a substantial rise in frequency and severity of presentation of youth-onset type 2 diabetes

SN Magge , RM Wolf , L Pyle , EA Brown , VC Benavides , ME Bianco , LC Chao , A Cymbaluk , PG Balikcioglu , K Halpin , DS Hsia , L Huerta-Saenz , JJ Kim , S Kumar , LE Levitt--Katz , BE Marks , A Neyman , KL O'Sullivan , SS Pillai , AS Shah , AH Shoemaker , JAW Siddiqui , S Srinivasan , IH Thomas , JB Tryggestad , MF Yousif , MM Kelsey , COVID-19 and Type 2 Diabetes Consortium Kelsey

Brief summary: A significant increase in the incidence T2D occurred in the USA during the COVID-19 pandemic, particularly among children with obesity and males.Comment: This is the first multicenter report on the incidence of T2D during the first year of the COVID-19 pandemic in the USA. The average number of new diagnoses per year in the two pre-pandemic years was 825, compared with 1463 during the first pandemic year. This increase of 77% is significan...